# Nanoliposomal Irinotecan (Nal-IRI, ONIVYDE®) in Combination With TAS-102 (LONSURF®) in Refractory Solid Tumors

> **NCT03810742** · PHASE1 · COMPLETED · sponsor: **PharmaEngine** · enrollment: 44 (actual)

## Conditions studied

- Refractory Solid Tumors

## Interventions

- **DRUG:** Nanoliposomal Irinotecan

## Key facts

- **NCT ID:** NCT03810742
- **Lead sponsor:** PharmaEngine
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-03-05
- **Primary completion:** 2022-05-04
- **Final completion:** 2023-10-25
- **Target enrollment:** 44 (ACTUAL)
- **Last updated:** 2023-11-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03810742

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03810742, "Nanoliposomal Irinotecan (Nal-IRI, ONIVYDE®) in Combination With TAS-102 (LONSURF®) in Refractory Solid Tumors". Retrieved via AI Analytics 2026-08-11 from https://api.ai-analytics.org/clinical/NCT03810742. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*